Oral pseudomembranous candidiasis, herpes simplex virus‐1 infection, and oral mucositis in head and neck cancer patients receiving radiotherapy and granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) mouthwash

Nicolatou‐Galitis, Ourania; Dardoufas, K.; Markoulatos, Panagiotis; Sotiropoulou-Lontou, Anastasia; Kyprianou, Konstantinos; Kolitsi, Georgia; Pissakas, George; Skarleas, Christos; Kouloulias, Vassilis; Papanicolaou, V.S.; Nj, Legakis; Velegraki, Aristea

doi:10.1034/j.1600-0714.2001.030008471.x

Cited by 63 publications

(84 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This may happen due to inclusion of different tumour types, patients with different protocol treatments for RT and/or chemotherapy, collection of oral rinsing samples performed at distinct moments, and lack of serological data [16,17,26]. …”

Section: Discussionmentioning

confidence: 99%

Oral shedding of human herpesviruses in patients undergoing radiotherapy/chemotherapy for head and neck squamous cell carcinoma is not affected by xerostomia

Palmieri

Ornaghi

Martins

et al. 2018

Journal of Oral Microbiology

View full text Add to dashboard Cite

Background: Xerostomia is a very relevant and frequent complication of radiotherapy, causing the irradiated oral mucosa to be affected by bacterial, fungal and viral infections. Objective: The objective of this study was to evaluate a possible relationship between oral shedding of human herpesviruses and xerostomia in patients with squamous cell carcinoma of head and neck submitted to radio/chemotherapy. Methods: In this study, oral rinse samples were collected weekly from 20 patients during radiotherapy. The samples were submitted to PCR and enzymatic digestion for detection of human herpesviruses. Xerostomia was evaluated according to the Seminars in Radiation Oncology criteria. Results: There was a higher frequency of grade 1 xerostomia (51.4%), observed first in the 1st week of radiotherapy. In the 4th week of radiotherapy, all patients presented some degree of xerostomia. Analysis of herpesviruses showed oral shedding of EBV, HHV-6 and HHV-7 in all weeks. Considering all the periods, the highest frequency was in patients with EBV excretion (55.0%), which was significantly higher than that of other viruses. Conclusion: We observed that oral shedding of herpesviruses was not affected by xerostomia as there was a progression in their excretion, even with the evolution of xerostomia. This suggested that there is a local replication in the oral cavity that is not completely dependent of salivary excretion.

show abstract

Section: Discussionmentioning

confidence: 99%

Oral shedding of human herpesviruses in patients undergoing radiotherapy/chemotherapy for head and neck squamous cell carcinoma is not affected by xerostomia

Palmieri

Ornaghi

Martins

et al. 2018

Journal of Oral Microbiology

View full text Add to dashboard Cite

show abstract

“…However, the panel decided that a guideline against the use of GM-CSF mouthrinses in all patients treated with various stomatotoxic CT regimens was not possible, since only one site-specific and highly mucotoxic CT regimen was evaluated in this study. Nicolatou-Galitis et al [57,58] reported results from a case series suggesting a preventative effect of GM-CSF mouthwashes on mucositis in patients receiving RT for H&N cancer, whereas controlled studies by Saarilahti et al and Mantovani et al [59,60] reported only a marginal effect. In contrast, Sprinzl et al [61] found no benefit ( Table 1).…”

Section: Granulocyte Colony-stimulating Factormentioning

confidence: 94%

Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients

Raber-Durlacher

Bültzingslöwen²,

Logan

et al. 2012

Support Care Cancer

113

View full text Add to dashboard Cite

Purpose The aim of this project was to review the literature and define clinical practice guidelines for the use of cytokines and growth factor agents for the prevention or treatment of oral mucositis induced by cancer chemotherapy or radiotherapy. Care Cancer (2013) 21:343-355 DOI 10.1007/s00520-012-1594 following three guideline determinations was possible: Recommendation, Suggestion, No guideline possible. Results Sixty-four clinical studies across 11 interventions were evaluated. A recommendation was made for the use of recombinant human KGF-1 (palifermin) at a dose of 60 μg/kg per day for 3 days prior to conditioning treatment and for 3 days post-transplant for prevention of oral mucositis in patients receiving high-dose chemotherapy and total body irradiation followed by autologous stem cell transplantation for hematological malignancies. A suggestion was made against using granulocyte macrophage colony-stimulating factor mouthwash for the prevention of oral mucositis in the setting of high-dose chemotherapy followed by autologous or allogeneic stem cell transplantation. No guideline was possible for any other cytokine or growth factor agents due to inconclusive evidence. Conclusions Of the cytokine and growth factor agents studied for oral mucositis, the evidence only supports use of palifermin in the specific population listed above. Additional welldesigned research is needed on other cytokine and growth factor interventions and in other cancer treatment settings. Methods

show abstract

“…For example, agents that promote invasion of phagocytic cells into the biofilm, in combination with glycocalyxreducing drugs, may increase the effectiveness of treatment in biofilm-associated skin infections [57]. Along these lines, the beneficial effects of a granulocyte-macrophage colonystimulating factor-based mouthrinse was shown recently in radiation-treated patients with pseudomembranous candidiasis [59].…”

Section: Therapeutic Challenges In Mucosal Biofilm Infectionsmentioning

confidence: 99%

Pathogenesis of mucosal biofilm infections: challenges and progress

Dongari-Bagtzoglou¹

2008

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

Living-tissue biofilms remained unrecognized until very recently, mainly as a result of traditional microbial sampling techniques or histologic processing, which disrupt the spatial organization of the tissue microorganisms. Thus, the biofilm nature of certain mucosal infections was frequently unintentionally missed or disregarded. To a large extent, the study of human tissue biofilms is still in its infancy. However, with the advent of newer methodologies, such as fluorescent in situ hybridization and endoscopic confocal laser scanning microscopy, which combine the identification of microbes with in situ, direct visualization of their relationships with each other and with their substratum, mucosal tissue biofilms are becoming easier to study and, thus, their role in human infections is becoming more apparent. This review summarizes the challenges in the study of tissue biofilms, proposes two inflammation-centered -albeit opposite -pathogenetic models of mucosal tissue biofilm infections and suggests directions for future research and novel therapeutic approaches.

show abstract

Oral pseudomembranous candidiasis, herpes simplex virus‐1 infection, and oral mucositis in head and neck cancer patients receiving radiotherapy and granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) mouthwash

Cited by 63 publications

References 24 publications

Oral shedding of human herpesviruses in patients undergoing radiotherapy/chemotherapy for head and neck squamous cell carcinoma is not affected by xerostomia

Oral shedding of human herpesviruses in patients undergoing radiotherapy/chemotherapy for head and neck squamous cell carcinoma is not affected by xerostomia

Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients

Pathogenesis of mucosal biofilm infections: challenges and progress

Contact Info

Product

Resources

About